Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics
Journal of Cutaneous Medicine and Surgery · 30.03.2026
DOI: 10.1177/12034754261436022 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Cutaneous Medicine and Surgery, online erschienen am 30.03.2026. Verfasst von Zaryab Alam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M College of Medicine, Bryan, TX, USA. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Texas A&M College of Medicine, Bryan, TX, USA.
- School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Center for Clinical Studies, Webster, TX, USA.
- Department of Dermatology, University of Texas Health and Sciences Center at Houston, Bellaire, TX, USA.
ORCID-Profile: Zaryab Alam
Zitieren
APA
Alam, Z., Nguyen, K. T., Verma, K. K., Tarbox, M. B., & Tyring, S. K. (2026). Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754261436022
Vancouver
Alam Z, Nguyen KT, Verma KK, Tarbox MB, Tyring SK. Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics. Journal of Cutaneous Medicine and Surgery. 2026. doi:10.1177/12034754261436022
BibTeX
@article{Alam2026,
author = {Alam, Zaryab and Nguyen, Kevin T and Verma, Kritin K and Tarbox, Michelle B and Tyring, Stephen K},
title = {Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2026},
doi = {10.1177/12034754261436022}
}
EUVIMED